Treatment of refractory adrenocortical carcinoma with thalidomide: analysis of 27 patients from the European Network for the Study of Adrenal Tumours Registry
M Kroiss, T Deutschbein, W Schlötelburg… - Experimental and …, 2019 - thieme-connect.com
Objective Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. In
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry
M Kroiss, T Deutschbein… - Experimental and …, 2019 - epub.ub.uni-muenchen.de
Objective Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. In
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry
M Kroiss, T Deutschbein, W Schlötelburg… - Experimental and …, 2018 - folia.unifr.ch
Objective Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. In
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry.
M Kroiss, T Deutschbein, W Schlötelburg… - … & Diabetes: Official …, 2018 - europepmc.org
Objective Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. In
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry
M Kroiss, T Deutschbein… - … & diabetes: official …, 2019 - pubmed.ncbi.nlm.nih.gov
Objective Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. In
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry
M Kroiss, T Deutschbein, W Schlötelburg… - Experimental and …, 2019 - zora.uzh.ch
OBJECTIVE Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis.
In advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often …
In advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often …
Treatment of refractory adrenocortical carcinoma with thalidomide: analysis of 27 patients from the European Network for the Study of Adrenal Tumours Registry
M Kroiss, T Deutschbein… - Experimental and …, 2018 - research.birmingham.ac.uk
Objective Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. In
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry
M Kroiss, T Deutschbein, W Schlötelburg… - Experimental and …, 2019 - thieme-connect.com
Objective Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. In
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry
M Kroiss, T Deutschbein, W Schlötelburg… - … Clinical Endocrinology & …, 2018 - sonar.ch
Objective Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. In
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …
advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary …